Safety of Upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies.

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies – Journal of Allergy and Clinical Immunology

Related: Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials – JAMA Dermatology